Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab in Previously Treated HER2-expressing Solid Tumors
NCT06695845Phase 2Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of zanidatamab in solid tumor, breast cancer, gastric cancer (GC), esophageal cancer, colorectal cancer (CRC), sponsored by Jazz Pharmaceuticals plc. Started Jan 2025; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
solid tumorbreast cancergastric cancer (GC)esophageal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06695845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695845.